Events and Presentations
Session: MASLD: Therapy (TOP-176)
Title: Concurrent Responses in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis Following Pemvidutide Treatment: 24-Week Responder Analyses from the Phase 2b IMPACT Trial
Speaker: Dr. Scot Roberts, Chief Scientific Officer, Altimmune
Session: MASLD: Therapy (FRI-201)
Title: Effect of Pemvidutide on Cardiovascular Risk Factors in Patients with MASH: 48-Week Results from the Phase 2b IMPACT Trial
Speaker: Dr. Shaheen Tomah, Director, Clinical Development, Altimmune
Session: MASLD: Clinical and Therapeutic Aspects I (OS-016)
Title: Week 48 Top-Line Results from the Phase 2b, Multicenter, Randomized, Placebo-Controlled IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
Speaker: Dr. Mazen Noureddin, Professor of Medicine, Houston Methodist Hospital; Chief Scientific Officer and Co-Chairman, Summit Clinical Research
Session: Late Breaker Posters (LBP-036)
Abstract Title: Pemvidutide Treatment Led to Fibrosis Regression After 24 Weeks in Patients with MASH: Quantitative Digital Pathology Analysis from the Phase 2b IMPACT Trial
Speaker: Dr. Shaheen Tomah, Director, Clinical Development, Altimmune
